First Things First for Locally Advanced Cutaneous Squamous Cell Carcinoma
PRIMO 2026 · CUTANEOUS ONCOLOGY
First Things First
For Locally Advanced Cutaneous Squamous Cell Carcinoma
After an initial response to immunotherapy, what treatment does a patient actually need?
About the talk
How much immunotherapy is enough, and which patients still need surgery or radiation? This presentation brings those practical questions into focus through the evolving treatment landscape for high-risk and locally advanced cutaneous squamous cell carcinoma (CSCC) and the Miller Lab’s institutional FIRST experience.
Frontline Immunotherapy with Response-Guided Subsequent Treatment (FIRST) provides a framework for approaching these decisions: begin with immunotherapy, reassess the response, and individualize what comes next. Subsequent management may include more immunotherapy, surgery, radiation, or close observation.
The talk moves from the clinical evidence to the challenges of interpreting an observational cohort. It introduces causal diagrams as a way to make clinical assumptions explicit and Bayesian analysis as a way to examine the probability and magnitude of potential benefit. The goal is to inform a thoughtful conversation about the least treatment needed to preserve durable disease control.
Questions explored
- How much additional benefit might another dose of immunotherapy provide?
- Which response findings support observation, and which call for local treatment?
- How can causal reasoning and Bayesian analysis improve the interpretation of clinical evidence?
Presenter
David M. Miller, MD, PhD
Presentation details
Program
PRIMO 2026
Date
Thursday, November 5, 2026
Presenter
David M. Miller, MD, PhD
Clinical focus
High-risk and locally advanced cutaneous squamous cell carcinoma
Approach
Early reassessment, response-guided treatment, and multidisciplinary decision-making
Research methods
Causal diagrams and Bayesian data analysis
This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement.